Friday 16 October 2026 Export TLSA’s income statement to Excel — free account

Tiziana Life Sciences Ltd

TLSA Healthcare Biotechnology

Insiders bought in the last twelve months.

1.06 0.01 +0.95%

Follow TLSA

Alert me

Market cap: $134.7M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	1	2	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 34.97%

Capital & Financial Ratios $m

Market Cap 134.73

Revenue —

Net Income (48.79)

Free Cash Flow (20.86)

Net Debt (4.01)

Current Ratio 0.76

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (6.11%)

Next Y EPS Growth (5.87%)

Next Y revenue growth —

Next 5Y EPS Growth (5.12%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/FCF against its own 10 years 45.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	18	1	4	4
Receivables	6	6	4	4
Inventory	—	—	—	—
Other	—	—	—	—
	24	7	8	9

	2022	2023	2024	2025
Payables	7	6	7	10
ST’ Debt	—	—	—	—
Other	0	0	0	0
	7	7	7	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(75.78%)	(86.15%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(13)
’24	—	—	—	—	(2)
’23	—	—	—	—	(16)
’22	—	—	—	—	(20)
’21	—	—	—	—	(22)
’20	—	—	—	—	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(7)	—	(13)	(13)
’24	—	0	—	(2)	(2)
’23	—	(11)	—	(16)	(16)
’22	—	(12)	—	(20)	(20)
’21	—	(13)	—	(22)	(22)
’20	—	(6)	—	(11)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.16)
’24	—	—	—	—	(0.11)
’23	—	—	—	—	(0.17)
’22	—	—	—	—	(0.15)
’21	—	—	—	—	(0.24)
’20	—	—	—	—	(0.27)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	1.13	0.67	0.62	0.85	0.53	0.50	0.41	0.63	Analyst estimates 2026–2028 Powerpack
	High	—	—	2.44	2.08	12.17	5.29	1.38	1.39	1.74	2.60
People
People	Employees	—	8	9	8	11	14	9	9	9	10
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(10)	(11)	(10)	(10)	(28)	(27)	(15)	(17)	(17)	(18)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(10)	(11)	(10)	(10)	(28)	(27)	(15)	(17)	(17)	(18)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.22)	(0.16)	(0.12)	(0.34)	(0.27)	(0.24)	(0.15)	(0.17)	(0.11)	(0.16)
	Cash flow	(0.16)	(0.14)	(0.07)	(0.25)	(0.12)	(0.22)	(0.19)	(0.15)	(0.01)	(0.11)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.16)	(0.14)	(0.07)	(0.25)	(0.12)	(0.22)	(0.19)	(0.15)	(0.01)	(0.11)
	Book value	0.09	(0.04)	0.01	(0.20)	0.64	0.42	0.19	0.05	0.04	0.00
	Shares, m	44	53	64	27	97	98	103	104	107	118
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(7)	(8)	(5)	(7)	(11)	(22)	(20)	(16)	(2)	(13)
	Capex	0	0	—	0	0	0	—	—	0	0
	Free cash flow	(7)	(8)	(5)	(7)	(11)	(22)	(20)	(16)	(2)	(13)
Balance, $m
Balance, $m	Working capital	4	(2)	1	(6)	62	41	18	1	0	(3)
	Total debt	0	0	1	1	0	2	0	—	—	—
	Net debt	(5)	0	(5)	1	(65)	(42)	(18)	(1)	(4)	(4)
	Shareholders’ equity	4	(2)	1	(6)	62	41	20	6	4	0
Returns, %
Returns, %	ROA	(97.94)	(200.32)	(168.97)	(200.54)	(71.56)	(39.20)	(40.89)	(91.52)	(101.10)	(161.82)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(629.14)	(258.21)	(4,656.25)	0.00
	ROE	1,282.91	(963.09)	902.10	373.29	(91.89)	(45.18)	(50.61)	(140.92)	(250.49)	(924.32)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MSLE Satellos Bioscience Inc.	$145.1M	— (loss-making)	—	—	n/m	−65.66% (below 0%: shrinking)	99.26%	0.00%	Compare
MOLN Molecular Partners AG Sponsored ADR	$143.5M	— (loss-making)	— (loss-making)	−98.86% (below 0%: shrinking)	n/m	+23.77% (above 0%: growing)	0.00%	0.00%	Compare
ALXO ALX Oncology Holdings Inc.	$138.3M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+31.65% (above 0%: growing)	0.00%	0.00%	Compare
AVXL Anavex Life Sciences Corp.	$137.2M	— (loss-making)	—	—	n/m	+27.02% (above 0%: growing)	—	0.00%	Compare
KRRO Korro Bio, Inc.	$137.1M	— (loss-making)	— (loss-making)	−86.28% (below 0%: shrinking)	n/m	+12.07% (above 0%: growing)	100.00%	0.00%	Compare
ANTX AN2 Therapeutics, Inc.	$135.9M	— (loss-making)	—	—	n/m	+7.91% (above 0%: growing)	0.00%	0.00%	Compare
CUE Cue Biopharma, Inc.	$135.6M	— (loss-making)	— (loss-making)	+166.66% (above 0%: growing)	n/m	−742.65% (below 0%: shrinking)	100.00%	(1,113.30%)	Compare
TLSA Tiziana Life Sciences Ltd	$134.7M	— (loss-making)	—	—	−258.11% (below 0%: shrinking)	+18.03% (above 0%: growing)	0.00%	—
ABOS Acumen Pharmaceuticals, Inc.	$120.8M	— (loss-making)	—	—	n/m	+43.23% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$137.1M	—	—	−92.57%	—	+17.92%	0.00%	0.00%

All 614 Biotechnology stocks →

Tiziana Life Sciences Ltd (TLSA) key facts

Tiziana Life Sciences Ltd (TLSA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 15, 2026, TLSA traded at $1.04, a market capitalization of $134.7 million.
Return on equity was −924.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.